Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | HINT1 | P49773 | 5/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.54 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.54 |
| ▸ | GSK3A | P49840 | 2/20 | 0.48 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971988 | 1.00 | TAS1R3 (0.56) | TAS1R3TAS1R1HINT1HPGDADORA3 | |
| SCHEMBL8930301 | 0.88 | TAS1R3 (0.56) | TAS1R3TAS1R1HINT1HPGDADORA3 | |
| SCHEMBL8930298 | 0.88 | TAS1R3 (0.56) | TAS1R3TAS1R1HINT1HPGDADORA3 | |
| SCHEMBL3180065 | 0.86 | POLA1 (0.54) | TAS1R3TAS1R1HINT1ADORA3ADORA1 | |
| SCHEMBL12729619 | 0.86 | POLA1 (0.54) | TAS1R3TAS1R1HINT1ADORA3ADORA1 | |
| SCHEMBL3180060 | 0.86 | POLA1 (0.54) | TAS1R3TAS1R1HINT1ADORA3ADORA1 | |
| SCHEMBL5353859 | 0.85 | TAS1R3 (0.47) | TAS1R3TAS1R1HINT1HPGDADORA3 | |
| SCHEMBL8930105 | 0.83 | HINT1 (0.59) | TAS1R3TAS1R1HINT1HPGDADORA3 | |
| SCHEMBL8930109 | 0.83 | HINT1 (0.59) | TAS1R3TAS1R1HINT1HPGDADORA3 | |
| SCHEMBL8448871 | 0.83 | HINT1 (0.49) | TAS1R3TAS1R1HINT1HPGDADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10287313-B2 | RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2019-05-14 | — | — | US | disclosed |
| US-20160340382-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-11-24 | — | — | US | disclosed |
| EP-2334692-B1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | UNIV MCGILL (CA) | 2016-04-13 | — | — | EP | disclosed |
| US-9249175-B2 | RNA monomers containing O-acetal levulinyl ester groups and their use in RNA microarrays | THE ROYAL INSTITUTE FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-02-02 | — | — | US | disclosed |
| CN-102639552-A | RNA monomer containing O-acetal levulinyl ester group and application thereof in RNA microarray | UNIV MCGILL | 2012-08-15 | — | — | CN | disclosed |
| US-20120178638-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2012-07-12 | — | — | US | disclosed |
| EP-2334692-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | The Royal Institution for the Advancement of Learning / McGill University (CA) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010025566-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287313-B2 | RNA monomers containing 0-acetal levulinyl ester groups and their use in RNA microarrays | EFTUD2, RNMT, NSUN2 | TAS1R3 3717/4885TAS1R1 4056/4885HINT1 3686/4885 |
| US-20160340382-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | EFTUD2, RNMT, RNGTT | TAS1R3 3786/4885TAS1R1 4180/4885HINT1 3729/4885 |
| US-20120178638-A1 | RNA MONOMERS CONTAINING O-ACETAL LEVULINYL ESTER GROUPS AND THEIR USE IN RNA MICROARRAYS | EFTUD2, RNMT, RNGTT | TAS1R3 3786/4885TAS1R1 4180/4885HINT1 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.